Benitec Biopharma Inc. Common Stock
BNTCBenitec Biopharma Inc. (BNTC) is a biotechnology company focused on developing gene-based therapeutics. It specializes in innovative DNA-based methods, particularly RNA interference (RNAi) technology, to target genetic and viral diseases. The company's approach aims to leverage gene silencing for therapeutic benefits across various medical conditions.
Company News
Benitec Biopharma announced positive 24-month follow-up results from its BB-301 gene therapy clinical trial for oculopharyngeal muscular dystrophy (OPMD). Patient 1 demonstrated deepening improvements in swallowing function with 60% reduction in post-swallow residue and 78% improvement in dysphagic symptom burden at 24 months. All four patients w...
Benitec Biopharma reported positive Phase 1b/2a trial results for BB-301, a gene therapy targeting Oculopharyngeal Muscular Dystrophy (OPMD), with a 100% responder rate. The FDA granted Fast Track Designation, and the company raised $100 million to advance the therapy's development.
Benitec Biopharma will provide an update on its Phase 1b/2a clinical study for BB-301, a gene therapy treatment for Oculopharyngeal Muscular Dystrophy, focusing on results from six patients in Cohort 1.
Benitec Biopharma announced the acceptance of a late-breaking oral abstract for the BB-301 Phase 1b/2a clinical study in Oculopharyngeal Muscular Dystrophy (OPMD) patients. Interim clinical study updates for the first three subjects will be presented at the Muscular Dystrophy Association Clinical and Scientific Conference in March 2025.
The global RNA-based therapeutic market is expected to grow from $9.46 billion in 2025 to $40.81 billion by 2034, driven by the rising prevalence of genetic disorders and the demand for personalized medicine. North America and Asia Pacific are the key regional markets.
